Pragmatic clinical trials embedded in healthcare systems: generalizable lessons from the NIH Collaboratory by Weinfurt, Kevin P. et al.
Pragmatic clinical trials embedded
in healthcare systems: generalizable
lessons from the NIH Collaboratory
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Weinfurt, K. P., A. F. Hernandez, G. D. Coronado, L. L. DeBar, L. M.
Dember, B. B. Green, P. J. Heagerty, et al. 2017. “Pragmatic clinical
trials embedded in healthcare systems: generalizable lessons from
the NIH Collaboratory.” BMC Medical Research Methodology 17
(1): 144. doi:10.1186/s12874-017-0420-7. http://dx.doi.org/10.1186/
s12874-017-0420-7.
Published Version doi:10.1186/s12874-017-0420-7
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:34492025
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
RESEARCH ARTICLE Open Access
Pragmatic clinical trials embedded in
healthcare systems: generalizable lessons
from the NIH Collaboratory
Kevin P. Weinfurt1,2,3*, Adrian F. Hernandez2,4, Gloria D. Coronado5, Lynn L. DeBar5, Laura M. Dember6,
Beverly B. Green7, Patrick J. Heagerty8, Susan S. Huang9, Kathryn T. James8, Jeffrey G. Jarvik8, Eric B. Larson10,
Vincent Mor11, Richard Platt12, Gary E. Rosenthal13, Edward J. Septimus14, Gregory E. Simon7, Karen L. Staman15,
Jeremy Sugarman16, Miguel Vazquez17, Douglas Zatzick18 and Lesley H. Curtis2,4
Abstract
Background: The clinical research enterprise is not producing the evidence decision makers arguably need in a
timely and cost effective manner; research currently involves the use of labor-intensive parallel systems that are
separate from clinical care. The emergence of pragmatic clinical trials (PCTs) poses a possible solution: these large-
scale trials are embedded within routine clinical care and often involve cluster randomization of hospitals, clinics,
primary care providers, etc. Interventions can be implemented by health system personnel through usual
communication channels and quality improvement infrastructure, and data collected as part of routine clinical care.
However, experience with these trials is nascent and best practices regarding design operational, analytic, and
reporting methodologies are undeveloped.
Methods: To strengthen the national capacity to implement cost-effective, large-scale PCTs, the Common Fund of
the National Institutes of Health created the Health Care Systems Research Collaboratory (Collaboratory) to support
the design, execution, and dissemination of a series of demonstration projects using a pragmatic research design.
Results: In this article, we will describe the Collaboratory, highlight some of the challenges encountered and
solutions developed thus far, and discuss remaining barriers and opportunities for large-scale evidence generation
using PCTs.
Conclusion: A planning phase is critical, and even with careful planning, new challenges arise during execution;
comparisons between arms can be complicated by unanticipated changes. Early and ongoing engagement with
both health care system leaders and front-line clinicians is critical for success. There is also marked uncertainty
when applying existing ethical and regulatory frameworks to PCTS, and using existing electronic health records for
data capture adds complexity.
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Background
High-quality evidence regarding the risks and benefits of
treatments is lacking across a multitude of clinical
specialties [1–7], and the clinical research enterprise is
not focused on generating the kind of information that
drives national guidelines for clinical care. Similarly,
traditional clinical trials are often unable to provide
high quality evidence in a timely or cost-effective
manner [8, 9]. High quality evidence is typically gener-
ated by conducting randomized controlled trials (RCTs)
using costly stand-alone, non-reusable systems, which
may be separate from clinical care, designed with rigorous
inclusion and exclusion criteria, and conducted under
ideal conditions [10]. These design features are a double-
edged sword: they help ensure that findings reflect true
variation as a result of an intervention, but have been criti-
cized as being so specific as to not be generalizable to
broader populations and settings. Many are calling for a
change, including the National Academies of Medicine
(formerly the Institute of Medicine), to a system in which
data for research are gathered during routine clinical care
to enable continual learning, i.e., a “learning healthcare
system” [11].
Pragmatic clinical trials (PCTs) are trials that use data
collected in the electronic health record (EHR) as part of
routine care, or are “embedded” in routine care, and are
a foundational component of such a system. By their na-
ture, PCTs are designed to show real-word effectiveness
in broad, generalizable patient groups (as opposed to the
more restricted protocols and populations found in
exploratory randomized trials) [12]. These PCTs have
the potential to significantly decrease the evidence gap
and inform real-world practice with digital health data
collected at the point of care. They involve critical part-
nerships between health care systems and academic in-
vestigators to embed clinically meaningful research
questions into the infrastructure of the health system to
generate real-world generalizable results in an efficient
manner.
While embedded PCTs hold great promise and much
work has been done to describe the continuum of prag-
matic versus explanatory trials for considerations in the
design phase of PCTs [13, 14], information summarizing
real-world experiences and best practices with PCTs is
scant; there is no clear framework for deciding when
PCTs would be optimal. The current ethical, regulatory
and logistical systems were created primarily with more
“traditional” RCTs in mind [15], and policy makers are
still working to understand the unique challenges associ-
ated with PCTs. To speed this learning process, the
Common Fund of the National Institutes of Health
(NIH) created the Health Care Systems Research Colla-
boratory (Collaboratory) in 2012. The Collaboratory’s
mission is to strengthen the national capacity to
implement cost-effective, large-scale PCTs, by support-
ing the design and execution of a series of pragmatic tri-
als, or demonstration projects (Table 1), with the intent
to learn how best to design, conduct, and disseminate
the results of these PCTs. To date, the Collaboratory has
funded the ten demonstration projects described here
and worked with the Project Principal Investigators (PIs)
to overcome challenges and barriers to designing, con-
ducting, and disseminating results from their PCTs. In
addition, an NIH funding opportunity announcement
(RFA-RM-16-019) was developed as a part of the Com-
mon Fund initiative to support more projects over the
next several years. These projects address questions of
public health importance, include a large, generalizable
population of patients, and engage healthcare delivery
organizations as research partners [16]. Members of the
Collaboratory Core Groups (described in more detail
below) worked with the PIs to facilitate the PCTs and
have reported on solutions to the challenges encoun-
tered. These include a special issue on the ethics of re-
search in usual care settings [17, 18], a special issue on
the ethical and regulatory complexities of pragmatic
clinical trials [15, 19–29], journal articles on initiating
and implementing patient-reported outcomes measures
[30], electronic health records, phenotyping, and inform-
atics [31–33], stakeholder engagement and health care
systems interactions [34–37], as well as biostatistical les-
sons learned on cluster and constrained randomization
[38, 39]. Members of the Collaboratory have also devel-
oped a Living Textbook on the design, conduct, and dis-
semination of PCTs (http://rethinkingclinicaltrials.org/).
Although there have been numerous publications de-
scribing nuanced challenges and solutions encountered
in the conduct of specific Demonstration Projects, this is
the first to widen the focus and describe the NIH
Collaboratory more generally. We build on the know-
ledge created by the Cores to review important
generalizable lessons learned over the first four years
since the Collaboratory was established. We also discuss
the remaining opportunities and challenges for the
Collaboratory and its forthcoming projects, and for the
medical community more broadly regarding PCTs to
power a learning health system.
Rationale and organization of the NIH Collaboratory
To provide expertise to the NIH Collaboratory Demon-
stration Projects, the following working groups, or Cores
were created to explore key elements of PCTs: electronic
health records; phenotypes, data standards and data
quality; patient-reported outcomes; health care systems
interactions; ethics & regulatory; biostatistics and study
design; and stakeholder engagement. The Collaboratory
Coordinating Center at the Duke Clinical Research In-
stitute (with colleagues at the Johns Hopkins Berman
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Institute of Bioethics, Harvard Pilgrim Health Care Insti-
tute, Group Health Research Institute/Kaiser Perma-
nente Washington Health Research Institute, Center for
Medical Technology Policy, and Medical College of Wis-
consin) serves 3 roles: (1) to provide support to the dem-
onstration projects to help ensure success; (2) to cull
Table 1 NIH Collaboratory Demonstration Projects
Study name Project goal Population Randomization
2012
Pain Program for Active
Coping and Training
(PPACT; NCT02113592)
Help patients adopt self-management skills
for chronic pain, limit use of opioid medica-
tions, and identify factors amenable to
treatment in the primary care setting [2]
Patients with chronic pain on
long-term opioid therapy
(~1000+ patients) in three
staff model health plans
Cluster randomization by
primary care provider
Strategies and Opportunities
to Stop Colorectal Cancer in
Priority Populations
(STOP CRC; NCT01742065)
Improve the rates of colorectal-cancer
screening by mailing fecal immunochemical
testing tests to patients at Federally
Qualified Health Centers
Individuals eligible for screening per
the US Preventive Task Force
guidelines (~35,000 patients) in 26
Federally Qualified Health Center
clinics
Cluster randomization by
Federally Qualified Health
Center clinic
Suicide Prevention Outreach
Trial (SPOT; NCT02326883)
Compare outcomes in patients who receive
care-management or online skills training
for suicide prevention versus usual care in
three healthcare systems
Individuals at elevated risk for
suicide on a depressions scale
(~19,500 patients) in three large
healthcare systems
Individual randomization
Time to Reduce Mortality in
End-Stage Renal Disease
(TiME; NCT02019225)
Determine whether increasing the durations
of hemodialysis sessions reduces mortality
and hospitalization rates for patients
receiving maintenance hemodialysis care
Adults who have initiated treatment
with maintenance hemodialysis
within the past 120 days
(~6800 patients) in 266 dialysis
facilities operated by two dialysis
provider organizations
Cluster randomization by
dialysis facility
Lumbar Image Reporting
with Epidemiology
(LIRE; NCT02015455)
Determine if inserting epidemiological
benchmarks (essentially representing the
normal range) into lumbar spine imaging
reports reduces subsequent spine-related
tests and treatments
100 clinics
(~230,000 patients) in four health
systems
Cluster randomization by
clinic. Stepped-wedge
one-way crossover design
Active Bathing to
Eliminate Infection
(ABATE; NCT02063867)
Determine if using antiseptic bathing for all
patients plus nasal ointments for patients
harboring methicillin-resistant Staphylococ-
cus aureus (MRSA) reduces multidrug-
resistant organisms and bloodstream
infections
Patients in adult medical, surgical,
oncology, and step-down units.
(~600,000 patients) in 53 hospitals
Cluster randomization by
hospital
Blood Pressure Medication
Timing Study (BPMedTime)
To compare adverse cardiovascular events
in patients who are instructed to take
their currently prescribed once-daily
antihypertensive medications at bedtime
compared with patients who continue to
take their once-daily antihypertensive
medications in the morning or afternoon
Initial plan was to test this question
in 1000 patients, but to have enough
power, it was determined that 5000
patients were needed
This trial was not transitioned
to the implementation phase
2014
Pragmatic Trial of Video
Education in Nursing Homes
(PROVEN; NCT02612688)
Determine if showing advance care
planning videos in nursing homes affects
the rates of hospitalization among frail,
demented residents
2 nursing home health systems
(360 nursing homes) serving
long-stay (>12 months) patients with
advanced comorbid conditions
(~15,000 patients)
Cluster randomization by
nursing home
Improving Chronic Disease
management with Pieces
(ICD-Pieces; NCT02587936)
Improve care for patients with chronic
kidney disease, diabetes, and hypertension
by using a novel technology platform
(Pieces) that uses the electronic health
record to identify patients and by assigning
practice facilitators within primary care
practices or community medical homes
Patients with multiple co-morbid
conditions (chronic kidney disease,
diabetes, and hypertension; ~11,000)
in 124 primary care practices in four
healthcare systems
Stratified cluster
randomization of clinical
practices within health
systems
Trauma Survivors
Outcomes and Support
(TSOS; NCT01625416)
Coordinate care and improve outcomes for
trauma survivors with post-traumatic stress
disorder(PTSD) and comorbidity
Expect 40 patients at each center
(~960 patients) in 24 US trauma
centers
Cluster randomization by
trauma center. Stepped-
wedge one-way crossover
design
This table is based on a table previously published by the Collaboratory in a white paper titled Lessons Learned from the NIH Health Care Systems Research
Collaboratory Demonstration Projects and is used with permission [41].
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experiences and create generalizable solutions regarding
challenges in designing, conducting, and disseminating re-
sults from PCTs; and (3) to disseminate lessons learned,
tools, and other resources to the broader community, in-
cluding the creation of a Knowledge Repository and the
Living Textbook of Pragmatic Clinical Trials: Rethinking
Clinical Trials.
Collaboratory demonstration projects
There have been two funding opportunities so far, one
in 2012 and one in 2014, and we expect another funding
opportunity in 2017 to support 10 additional PCTs. In
2012, seven demonstration projects were funded (RFA-
RM-12-002, Table 1), and in 2014, three additional
demonstration projects were added to the Collaboratory
to focus on interventions that improve the health of
patients with multiple chronic conditions (RFA-RM-13-
012). In recognition of the challenge of conducting trials
in ongoing clinical care settings and other uncertainties
associated with their design, a two-phase, cooperative
agreement approach was used for their funding. In the
one-year planning phase, the demonstration project in-
vestigators refined their study protocols in cooperation
with other experts within the Collaboratory network and
Core groups, piloted aspects of the proposed designs,
and developed revised proposals for their projects that
were submitted to NIH. Projects deemed acceptable
were funded for the four-year execution phase. This
two-phase approach was beneficial in that it (1) drew on
the broader intellectual community of the Collaboratory
to contribute to the planning of each project, (2)
highlighted the questions and uncertainties that arise
during the planning of PCTs within healthcare systems,
and (3) increased the likelihood that the projects would
be successful in answering their scientific question.
A Spirit of openness
Because the Collaboratory pragmatic trial interventions
are tested in the context of routine medical care, data
are collected from the EHR and claims, and the studies
involve large sample sizes, the engagement of healthcare
delivery organizations, providers, researchers, and repre-
sentatives from the NIH (12 NIH institutes and centers
are involved) has been critical. The Collaboratory’s suc-
cess depends entirely on the willingness of investigators
to share their challenges in real time with the rest of the
network, including the NIH staff. This differs from many
research enterprises, in which investigators often feel
motivated to present an image of perfection to everyone
outside of their project and especially to the sponsors.
The Collaboratory projects were selected with the un-
derstanding that they would generate challenges that the
research community must learn to overcome. The trans-
formation of challenges into lessons learned that are
then shared with the broader community is a direct re-
sult of the good faith, generosity, and candor of the Col-
laboratory demonstration project investigators and their
health system partners.
Methods
The information regarding lessons learned was
gleaned from a number of sources. The Collaboratory
held yearly Steering Committee meetings (Bethesda,
MD, 2012–2107) in which all the Principal Investigators
(PIs) gather to share their experience and knowledge
through interviews and presentations. Members of the
Coordinating Center interview each of the PIs at these
meetings to gather lessons learned, and each PI presents
lessons learned at a general session followed by an oppor-
tunity for discussion. Leaders of each of the Cores also
hold monthly calls with the PIs and their teams to discuss
problems and explore solutions, and these lessons are
gathered as a part of minutes from the call. In addition, all
the PIs and some members of their teams are authors on
this paper.
Results: Lessons learned
A planning phase is essential
As one of the Collaboratory investigators said, nothing is
“plug and play” in a PCT within a healthcare system. In
all the Collaboratory demonstration projects, there were
important changes made to the protocol during the plan-
ning phase as a result of further engagement with stake-
holders, consultation with other experts, and collection of
pilot data.
In one of the first seven planning projects fun-
ded—the Blood Pressure Medication Timing Study
(BPMedTime)—the ultimate sample size needed was
determined to be 5000 versus the original 1000 sub-
jects in order to detect a lower effect rate than antici-
pated. Because this new sample size was too large to
be feasible within the budgetary constraints of the
funding mechanism, the BPMedTime trial was not
transitioned to the implementation phase; however, all
of the other demonstration projects were moved
forward.
Despite good planning, new challenges arise during
execution
Because PCTs occur in the dynamic environment of one
or more healthcare systems, changes can arise that
require modification of the protocols or how they are
implemented. Leadership changes, staff turnover, and
new local or national policies can all require a change of
plan. For example, after experiencing issues with study
implementation, the STOP CRC research team part-
nered with practice improvement facilitators who were
trained in the plan-do-study-act (PDSA) method [40].
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The facilitators held in-person meetings with leadership
teams from all sites and asked the sites to submit a
PDSA plan for issues with the trial. For example, when
there were too many fecal kits submitted without a col-
lection date, the “Plan” was to test new patient materials
that prompted patients to write the collection date on
the kits. PDSA cycles empowered clinics to identify and
address local problems and provided information about
implementation challenges, which improved study con-
duct [41]. Additionally, the PROVEN trial had excellent
experience integrating a new record documenting the
video being offered and shown in nursing homes’ EMR
during the pilot implementation, but this failed to reveal
that staff were keen to document that the videos were
offered even though far fewer patients were actually
viewing them. Mid-course corrections required a new
approach in which nursing home leadership became
even more involved in advocating for the goal of person-
alized advance care planning.
Early and ongoing engagement with the healthcare
system is critical
Collaboratory PCTs are conducted in real-world settings
and leverage the existing infrastructure (e.g., data sys-
tems) of healthcare systems to answer clinical questions
of importance to patients, providers, payers, and other
stakeholders. In these PCTs, the data originate from the
healthcare systems EHR and include proprietary infor-
mation, so strong and trusting partnerships are needed
between investigators and healthcare system leaders
[35]. While healthcare systems should be committed to
improving care for all their patients, they have oper-
ational priorities, finite financial resources and institu-
tional energy, and the physicians, leaders and staff in
most systems are already pressed for time attending to
patient needs. Early engagement with leaders of health-
care systems will facilitate systems identifying partners
to help align research goals with organizational goals
and performance improvement initiatives [10]. Assist-
ance at the level of the individual provider group is often
necessary to identify the best way to incorporate a new
intervention into standard-of-care operating procedures.
Early and ongoing engagement with clinicians is critical
Data are collected during the course of routine care, and
partnerships must be built with healthcare providers to
ensure that the intervention can be added into existing
workflows as seamlessly and with as little burden as pos-
sible [42]. Physicians, nurses, and other clinical staff who
will implement the protocol will have insight about the
feasibility and sustainability of the intervention [43]. For
example, the PPACT trial has an intervention that is
delivered in the primary care setting where schedules are
busy and space is tight. The research team partnered
with clinicians to understand the clinical workflow and
concerns of integrating research. As a result, they sched-
uled study-related patient visits during slower clinic pe-
riods and held patient visits in less conventional ways,
such as after hours and by having groups meet in lobby
spaces [41]. The TiME trial investigators found that even
small changes to work flow, such as incorporating
methods for documenting trial activities, were viewed as
large changes by facility staff, and required more effort
at the local level than had been anticipated. The
PROVEN trial initially asked facility admission staff to
incorporate offering and showing the video into the
standard admission process, but found that offering this
too early was challenging because the existing admission
process is already intense. Consequently, the team
altered the limits on when the video should be offered.
As another example, the investigative team with ICD-
Pieces initially planned for structured, step-wise
electronic tools that were time consuming but that
would provide a detailed therapy plan for patients; after
discussing the tool with medical directors and physi-
cians, they developed more user-friendly, less burden-
some tools [41]. The clinical decision support tools were
streamlined to rely on more user-friendly links to simple
workflows, targeted protocols, and related order sets.
Uncertainty arises when applying existing ethics and
regulatory frameworks to embedded pragmatic clinical
trials
High quality PCTs should provide meaningful answers
to important clinical questions while protecting the
rights and welfare of all research participants (which
may include clinicians in the case of cluster-randomized
studies) and complying with relevant policies and regula-
tions [44, 45]. As the Collaboratory trials were being
planned, discussions among investigators and institutional
and federal officials involved in human subjects oversight
highlighted several areas of ambiguity and, sometimes,
disagreement. These issues are reviewed in a series of
Collaboratory publications [15, 19–29, 46]. For example,
Institutional Review Board process for the SPOT trial took
10 months longer than was typical for large trials at the
host institution. The SPOT trial tests suicide prevention
strategies versus usual care in patients at risk for suicide,
and a fundamental issue arose regarding whether one
could conduct a minimal-risk study in a high-risk popula-
tion [47]. The TiME trial, which also enrolls a high-risk
population (patients with end-stage renal disease), was
faced with the question of whether a trial with an outcome
of mortality could be considered “minimal risk” [27]. For
both studies, it was ultimately decided that the incremen-
tal risk of the research could be considered minimal, in
part because both physicians and patients maintained
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autonomy with respect to implementation of the
intervention.
As another example, the data safety monitoring board
(DSMB) overseeing the TSOS trial initially wanted to
require the team to report every hospitalization as a ser-
ious adverse event, but in their cohort of people at risk
for post-traumatic stress disorder (PTSD), approximately
15–20% were expected to be re-hospitalized for non-
emergent reasons, and some negotiation was required
[41]. In the end, it was decided that only emergency hos-
pitalizations (e.g., hospitalization after a suicide attempt)
would be considered serious adverse events that re-
quired additional reporting.
There is clearly an opportunity for more learning and
reflection regarding the best way to promote the rights
and welfare of research participants in the context of
PCTs.
Comparisons between arms can be complicated
by unanticipated changes in either arm
In a traditional randomized, controlled trial, it is possible
to exert significant control over what happens in the dif-
ferent arms of the trial. Because the demonstration pro-
jects are tackling issues that are major public health
concerns, such as opioid prescribing and hospital-based
infections, competing initiatives are likely to be launched
at some of the study sites. Conversely, providers in the
experimental arm might resist the intervention due to
burden. Providers in the “usual care” arm might volun-
tarily adopt the trial intervention, especially if there is
growing evidence that the intervention is associated with
better outcomes. There were a number of opioid reduc-
tion related initiatives rolled out during the implementa-
tion of PPACT, thereby changing the nature of the
underlying usual care. In the words of Lynn DeBar, PI of
the PPACT trial: “Our control is not controlled. We
can’t control it, and that’s a big challenge [48].” For an-
other example, because observational data suggest that
longer hemodialysis sessions are beneficial, dialysis units
in the TiME trial, including some of those randomized
to usual care, have increased session durations for their
patients [41]. Staff turnover might result in interventions
being implemented in different ways over time and
across sites. As an example, in the PROVEN trial, some
participating nursing homes experienced multiple
changes in the advance care planning champion in the
first year of the study, requiring retraining and interrup-
tions in patients and family members being offered the
videos. It is not surprising, therefore, that facilities with
more champion turnover had lower rates of showing the
video, particularly to long-stay residents. For another
example, in the PPACT trial competing local initiatives
requiring highly skilled nurses or behavioral specialists
resulted in some instability in the intervention staffing
and, consequently, some variability in disciplines repre-
sented on the core interdisciplinary intervention team
across performance sites over time. These and other fac-
tors make it necessary to carefully monitor the activities
in all of the sites involved in the study, so that at the
very least it will be possible to describe the nature of
these changes that might affect the difference between
the arms.
Leveraging existing tools and electronic health
record systems adds complexity
Reliance on the EHR for data to support research
investigations is challenging for many reasons. First,
even when sites are a part of a single corporate entity,
local coding varies, and cross-site data standardization is
essential. Because no two electronic health record (EHR)
systems are alike, the solution requires engagement of
local data experts. Tools, such as the ones developed for
SPOT do not transfer from one site to another, and local
adaptation is necessary. Each health system may have a
distinct process or pathway for implementation of an
intervention, and a multi-site trial will need to adapt to
those. In the case of the SPOT trial, even though all of
the sites use Epic, they have different preferred methods
for implementing standardized assessment tools, and the
investigators needed to adapt to those different preferred
pathways.
Additionally, because the EHR is optimized for clinical
practice and sometimes billing, integrating study-related
data elements into the EHR has implications for clinical
workflow and compliance. A seemingly small change to
the work flow to accommodate a research project likely
could have major implications for the IT system. The in-
vestigators in LIRE, a study that adds epidemiological
benchmarks to lumbar spine imaging reports, found that
even minor modifications to reports met with initial
resistance since these required allocations of scarce IT
resources. Overcoming this sort of hurdle required close
coordination with site PIs and local leadership buy-in.
Some cases offer a different scenario: for PROVEN, the
two corporate partners use a different EHR but with the
help of devoted efforts from corporate leadership, were
able to add a new record into their EHR system to per-
mit staff to document each time the video was offered
and subsequently shown to the patient or family
members.
Discussion: Next steps and remaining opportunities
What Else do we need to learn about conducting
successful PCTs?
As the first round of demonstration projects approach
completion, the Collaboratory will continue to identify
challenges and lessons learned regarding health care sys-
tems interactions, data analysis, interpretation, reporting,
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and dissemination to inform the next set of demonstra-
tion projects and PCTs in general. These lessons will
inform other national evidence generation efforts that
are underway, such as the Patient-Centered Outcomes
Research Network (PCORnet). To understand the full
potential of PCTs to advance healthcare, additional
knowledge is needed about research designs that were
not a part of the first phase of Collaboratory, but may be
a part of the second phase:
A vs. B comparisons of treatments for individual patients
While the 9 Collaboratory trials test a variety of inter-
ventions, none involve simple comparisons between two
or more alternative medical products or treatments for
individual patients. There is an ongoing need to know
the comparative effectiveness of currently used individ-
ual therapies and the benefits and risks of medical prod-
ucts, and to understand how PCTs might help address
these needs. For example, trials that conduct head-to-
head comparisons between different classes of drugs for
the same condition—e.g., first line treatment for hyper-
tension [49]—could raise unique logistic, ethical, and
regulatory challenges that would be important to under-
stand and address.
Investigative teams with varying experience
The Collaboratory projects all benefitted from research
teams that were highly experienced in health services re-
search and clinical trials, and included national leaders
in their fields who had deep experience in integration of
research into health care delivery. Many of the teams
also had experience with their health system partners,
and having situation-specific experience was critically
important. For example, this experience helped the LIRE
investigators understand EHR idiosyncrasies and antici-
pate challenges, to build upon already established trust,
and to leverage previously collected data for pilot pur-
poses. The number of investigators with such back-
grounds is small relative to the large number of clinical
problems that might benefit from well-designed embed-
ded PCTs. Therefore, it is important to understand what,
if any, additional challenges might arise when teams with
less experience and expertise, or perhaps more import-
antly, less familiarity with the host delivery system,
attempt to design and conduct a PCT. Experience with
this broader population of researcher teams would be
useful.
Education and training in PCTs
Because there are few research teams with the know-
ledge and experience to conduct successful PCTs, it is
critical that experiences and best practices from the Col-
laboratory and other sources (e.g., PCORnet) are trans-
lated into education and training to create a larger pool
of competent research teams. Teaching people how to
conduct PCTs within healthcare systems will require an
understanding of how to partner with health care sys-
tems and the rapidly changing world of clinical care; the
success of a trial depends upon interactions and negotia-
tions with the leaders of healthcare systems of the sort
that cannot be taught in a classroom. Thoughtful
approaches are needed to develop experience-based
learning in the context of existing networks of PCT
trialists and to incentivize the few existing experts to
devote time to teaching and mentoring.
Need for core resources for new PCTs
Until we have learned how best to conduct PCTs in differ-
ent settings and enough research teams have been trained
in how to do so, new PCTs could benefit from a core re-
source to assist in planning and conducting the trials. In
the Collaboratory, the demonstration projects benefitted
from core expertise within the Coordinating Center dur-
ing the planning phase. Challenges continued to surface in
some of the trials during the implementation phase,
underscoring the importance of having a dedicated core
resource available throughout the conduct of a PCT. Such
a central resource could also be useful for accumulating
the knowledge and experience gleaned across multiple
PCTs in a wide range of settings, possibly leading to more
efficient and informative PCTs in the future.
Changing culture and incentive structures to make PCTs
easier to do
A number of barriers to successful PCTs are associated
with how incentives align with health systems, clinicians,
and potential sponsors. As healthcare systems become
more complex and larger, there are increasing demands to
ensure productivity is maintained for the system at large
and for clinicians, and it may be more difficult to achieve
alignment and to balance clinical obligations with the
added work of PCTs. In particular, new mandates on clin-
ician time, such as using EHRs, make it more difficult to
add new activities unless it is within the workflow. There
is often no clear framework for rewarding or reimbursing
clinicians to enable PCTs, especially if time is needed for
an intervention that is not directly reimbursed or
rewarded. Finally, it may be difficult for clinicians or
health systems to envision the direct impact a PCT may
have on their practice.
In order to make PCTs the norm rather than the excep-
tion, cultural changes and incentives are needed. Institu-
tional leadership could make developing, participating in,
and leading PCTs part of the strategic planning, which
generally emphasizes the importance for professional
growth and alignment with health system values. These
approaches have been used in the setting of healthcare
reform as payments shifted from volume-based care to
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value-based care, demonstrating behavior changes in both
the health systems as well as the clinicians supporting the
systems.
Conclusion
The NIH Collaboratory is an important part of the overall
effort to improve the national capacity to generate evi-
dence to inform healthcare decisions by patients,
providers, and payers. Even before the demonstration pro-
jects have completed their work, much has been learned.
Planning activities are substantial and should be supported
as part of a phased approach, such as the planning and
implementation phases used by NIH for the Collabora-
tory. New challenges frequently arise during execution;
change is the only constant, and because of this, early and
ongoing engagement with all stakeholders is critical. As
the new demonstration projects begin, we hope to learn
from these lessons and generate others, as there remain
opportunities for additional learning in order to make in-
telligent investments in PCTs. There is also the need to
train a new clinical trials workforce, to train reviewers for
PCTs, and align interests for all stakeholders to contribute
to a national evidence generation system.
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